Report Company Directory

Santander UK PLC Pfd. ABBEY NAT10.375PRF

• FirstBank UK Ltd - Company Profile and SWOT Analysis by MarketLine
• OneSavings Bank Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances by MarketLine
• Santander UK PLC: Post Rating Action Update by Moody's Investors Service
• Spanish banking group opportunity by Ambrosetti Asset Management SIM

Santec Corp

• Ford Equity International Rating and Forecast Report by Ford Equity Research

Santen Pharmaceutical Co. Ltd.

• 3Q results largely as expected, but sales of focus products fall short by Mizuho Securities
• 3Q決算：決算全体はほぼ想定線だが、注目製品の売上は想定を下回る by Mizuho Securities
• Mizuho Medical Report: 2026 healthcare investment strategy by Mizuho Securities
• Mizuho Medical Report：26年の医療業界各セクターの投資戦略 by Mizuho Securities
• Medical insights #12 - Methods of suppressing the progression of myopia in children by Nomura Research
• メディカル insights #12 - 小児の近視進行を抑制するデバイス by Nomura Research
• Near-term focus on market creation for myopia and ptosis treatments by Mizuho Securities
• 当面の注目点は、近視・眼瞼下垂治療薬の市場創出 by Mizuho Securities
• 1H results: in line, 2H recovery on end to Japan/China inventory correction by Mizuho Securities
• 上期決算：ほぼ予想線、日本・中国の在庫調整完了で下期回復 by Mizuho Securities

SANTEN PHARMACEUTICAL CO. LTD.

Santhera Pharmaceuticals

• Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy by GlobeNewsWire
• Santhera erhält Swissmedic-Zulassung für AGAMREE® (Vamorolon) zur Behandlung von Duchenne-Muskeldystrophie by GlobeNewsWire
• Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties by GlobeNewsWire
• Santhera lizenziert AGAMREE® (Vamorolon) an Nxera Pharma in Japan, Südkorea, Australien und Neuseeland im Rahmen eines Vertrags mit einem Wert von bis zu 205 Millionen US-Dollar zuzüglich Lizenzgebühren by GlobeNewsWire
• Santhera schliesst Lizenzgebührenvereinbarung über 13 Millionen US-Dollar ab by GlobeNewsWire
• Santhera Closes USD 13 Million Royalty Monetization Agreement by GlobeNewsWire
• Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids by GlobeNewsWire
• Fünfjahresdaten zu AGAMREE® (Vamorolon) bei Patienten mit DMD zeigen ein verbessertes Sicherheitsprofil bei vergleichbarer Wirksamkeit wie bei der Standardbehandlung mit Kortikosteroiden by GlobeNewsWire
• Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids by GlobeNewsWire
• Fünfjahresdaten zu AGAMREE® (Vamorolon) bei Patienten mit DMD zeigen ein verbessertes Sicherheitsprofil bei vergleichbarer Wirksamkeit wie bei der Standardbehandlung mit Kortikosteroiden by GlobeNewsWire